Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
Clinical trial NCT07410975 · RECRUITING
Trial details
- NCT number
- NCT07410975
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-10
- Primary completion
- 2028-06-10
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.